Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-05
2011-07-05
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021910, C514S017800, C514S017900
Reexamination Certificate
active
07973011
ABSTRACT:
Methods are provided for enhancing myelination. Myelination is enhanced by administration of agents that are inhibitors of γ-secretase. Methods of screening for pharmaceutically active compounds that enhance myelination, and for genes involved in myelination are also provided.
REFERENCES:
patent: 4963557 (1990-10-01), Badger et al.
patent: 2005/0048539 (2005-03-01), Hyman
patent: 2008/0233132 (2008-09-01), Miller et al.
Dovey 2001 (Journal of Neurochemistry 76:173-181).
Seubert 1993 (Nature 361:260-263).
Geling 2002 (EMBO Reports 3:688-694).
Wolfe 2001 (Journal of Molecular Neuroscience 17:199-204).
Lundkvist 2007 (Current Opinion in Pharmacology 7:112-118).
Jurynczyk; et al., “Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis”, Journal of Neuroimmunology, Dec. 30, 2005, 170(1):3-10.
Lai; et al., “Implication of gamma-secretase in neuregulin-induced maturation of oligodendrocytes”, Biochemical and Biophysical Research Communications, Feb. 6, 2004, 314(2):535-542.
Watkins; et al., “A New Co-Culture System of Purified Neurons and Oligodendrocytes for Examining CNS Myelination in vitro”, Abstracts of the Annual Meeting of the Society for Neuroscience, Nov. 7, 2002, program No. 448.9.
Cui et al., “NB-3/Notch1 pathway via deltex1 promotes neural progenitor cell differentiation into oligodendrocytes”, J. Biol. Chem., 2004, 279(24):25858-65.
Kimberly et al., “Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2”, Proc. Natl. Acad. Sci. USA, 2003, 100(11):6382-6387.
Lanz et al., “Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).”, J Pharmacol Exp Ther., 2004, 309 (1):49-55.
Leissring et al., “A Physiologic Signaling Role for the Gamma -Secretase-Derived Intracellular Fragment of APP”, Proc Natl Acad Sci USA, 2002, 99(7):4697-702.
Li et al., “Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1”, Nature, 2000, 405(6787):689-94.
McLendon, “Cell-free assays for gamma-secretase activity”, FASEB J., 2000, 14(15):2383-6.
Meyer-Franke et al., “Astrocytes induce oligodendrocyte processes to align with and adhere to axons”, Mol Cell Neurosci, 1999, 14(4-5), 385-97.
Milano et al., “Modulation of notch processing by g-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation”, Toxicological Sciences, 2004, 82:341-358.
Pinnix et al., “A novel gamma-secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor”, J. Biol. Chem, 2001, 276(1):481-7.
Schneider, “Palmitoylation is a sorting determinant for transport to the myelin membrane”, J Cell Sci, 2005, 118:2415-23.
Schroeter et al., “A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis”, Proc. Natl. Acad. Sci. USA, 2003, 100(22):13075-13080.
Shearmen et al., “L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity”, Biochemistry, 2000, 39(30):8698-8704.
Stidworthy et al., “Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination”, Brain, 2004, 127(Pt 9):1928-41.
Takahashi et al., J. Biol. Chem., “Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation”, 2003, 278(20):18664-70.
Wang et al., Neuron, “A role for the helix-loop-helix protein Id2 in the control of oligodendrocyte development”, 2001, 29(3):603-14.
Windrem et al., Nature Medicine, “Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain”, 2004, 10(1):93-97.
Wolfe et al., J. Med. Chem., “A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity”, 1998, 41(1):6-9.
Genoud; et al., “Notch1 control of oligodendrocyte differentiation in the spinal cord”, The Journal of Cell Biology (2002), 158(4):709-718.
Givogri; et al., “Central Nervous System Myelination in Mice With Deficient Expression of Notch1 Receptor”, Journla of Neuroscience Research (2002), 67:309-320.
Hohlfeld, “Myelin failure in multiple sclerosis: Breaking the spell of Notch”, Nature Medicine (2002), 8(10):1075-76.
Hu; et al., “F3/Contactin Acts as a Functional Ligand for Notch during Oligodendrocyte Maturation”, Cell (2003), 115:163-175.
John; et al., “Multiple sclerosis: Re-expression of developmental pathway that restricts oligodendrocyte maturation”, Nature Medicine (2002), 8(10):1115-1121.
Minter; et al., “Inhibitors of gamma-secretase block in vivo and in vito T helper type 1 polarization by preventing Notch upregulation of Tbx21”, Nature Immunology (2005), 6(7):680-688.
Popko, “Notch Signaling: A Rheostat Regulating Oligodendrocyte Differentiation”, Developmental Cell (2003), 5 (5):668-669.
Von Boehmer, “Notch in lymphopoiesis and T cell polarization”, Nature Immunology (2005), 6(7):641-642.
Wang; et al., Notch Receptor Activation Inhibits Oligodendrocyte Differentiation, Neuron (1998), 21:63-75.
Wang; et al., “Up a Notch: Instructing Gliogenesis”, Neuron (2000), 27:197-200.
Barres Ben A.
Watkins Trent Alan
Alcamo Elizabeth A.
Bozicevic Field & Francis LLP
Kolker Daniel E
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Blockade of gamma-secretase activity to promote myelination... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blockade of gamma-secretase activity to promote myelination..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blockade of gamma-secretase activity to promote myelination... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2647856